Introduction
Quality of life reduction is a major burden for patients with chronic hepatitis C [1] [2] [3] [4] [5] . Health surveys were performed and confirmed that the quality of life of patients with chronic hepatitis C is significantly impaired compared with the healthy population [1] [2] [3] [4] [5] . The current treatment options for quality of life reduction are not satisfactory.
The approved treatment for chronic hepatitis C is the combination of interferon-a (IFN-a) and ribavirin [6] [7] [8] leading to eradication of the hepatitis C virus (HCV) in approximately half of the treated patients [6, 7] . Success-ful viral eradication not only reduces the risk for further progression of liver disease [9] but also leads to significant improvement of health-related quality of life [10] [11] [12] . IFN-a-based antiviral treatment itself, however, causes a marked further deterioration of quality of life in treated patients [11] . The deterioration of quality of life during treatment is a significant problem because it is a frequent reason for reduced treatment adherence and premature discontinuation [10, 13] .
Amantadine is a tricyclic amine with antiviral activity against the influenza A virus and other viruses such as flaviviridae to which HCV belongs [14, 15] . Several
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clinical trials with amantadine in combination with IFN-a alone or in combination with ribavirin for the treatment of patients with chronic hepatitis C have been conducted but produced conflicting results on additional antiviral activity [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
Amantadine improves neurological symptoms of Parkinson's disease, for example, rigor, tremor, fatigue [29] [30] [31] , and fatigue in patients with multiple sclerosis [32] . It was hypothesized that amantadine may improve healthrelated quality of life in patients with chronic hepatitis C during and after antiviral therapy [20, 26, 28, 33] . In two trials, the addition of amantadine to IFN-a monotherapy reduced deterioration of quality of life during and after treatment with standard IFN-a [26, 28] .
This study was performed to clarify whether the addition of amantadine to IFN-a and ribavirin reduces deterioration of quality of life during treatment and whether the addition of amantadine leads to sustained improvement of quality of life after the end of combination therapy with IFN-a and ribavirin. Furthermore, we investigated whether the effect of amantadine on quality of life during and after treatment is associated with virologic response.
Patients and methods

Patients
Female and male patients with compensated chronic hepatitis C who had not been previously treated with IFN-a, ribavirin and/or amantadine were enrolled for this study. The following criteria had to be fulfilled: age between 18 and 70 years, a positive test for anti-HCV (second-generation enzyme immunoassay) and HCV-RNA by reverse-transcription polymerase chain reaction [Amplicor HCV (version 2), Roche Diagnostics, Branchburg, New Jersey, USA], elevated serum alanine aminotransferase levels for at least 6 months before initiation of treatment, a liver biopsy taken in the preceding year, and a completed quality of life questionnaire before treatment. Exclusion criteria were decompensated liver cirrhosis, other causes of liver disease, HIV infection, autoimmune disorders, pregnancy, lactation period, and severe other comorbidities such as neoplastic, cardiac, hematologic, and psychiatric diseases. Patients with alcohol or active drug abuse were also excluded.
Study design
This study was part of a randomized, double-blind, placebo-controlled trial that was conducted at eight centers (seven university hospitals and one general hospital) in Germany [17] . From the 400 patients that were treated in the original study, 267 patients participated in the quality of life assessment. The trial profile is illustrated in Fig. 1 . Patients were randomly allocated to receive treatment with a total dose of 200 mg amantadine sulphate (100 mg twice daily orally; Infex; Merz & Co.
GmbH, Frankfurt a.M., Germany) or a matched placebo. Furthermore, all patients were treated with IFN-a2a (Roferon A; Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany) plus 1000-1200 mg ribavirin per day orally adjusted according to body weight (1000 mg for weight below 75 kg and 1200 mg for weight 75 kg or more) for 48 weeks. For the first 2 weeks, all patients received nine million units (MU) IFN-a daily, followed by 6 MU IFN-a daily for an additional 6 weeks. After the initial daily induction period, the dose of IFN-a was reduced, and 6 MU were given three times per week until week 24 and then 3 MU three times per week for further 24 weeks. Patients were followed-up for further 24 weeks after treatment. Treatment was prematurely discontinued in patients with detectable HCV-RNA 24 weeks after initiation of therapy. Sustained virologic response was defined as undetectable HCV-RNA 24 weeks after the end of treatment. End of treatment response was defined as undetectable HCV-RNA at the end of treatment but relapse thereafter. Virologic nonresponse was defined as detectable HCV-RNA during and after treatment.
The study received ethics committee approval at each center according to the Declaration of Helsinki, and the patients provided written informed consent.
Health-related quality of life assessment
Psychologic states were measured by the German adapted and validated version of the 'Profile of Mood States' (POMS) scale, which measures four factor scores for depression, fatigue, vigor, and anger [34, 35] . Furthermore, quality of life was assessed by the 'Everyday Life' questionnaire (EDLQ), a German validated questionnaire related to the SF-36 Health Survey [36, 37] . The EDLQ assesses the following six subscales: body (e.g. make demands on body, concentrate on a task); mind (e.g. cope with illness, accept oneself); everyday life (e.g. solve daily problems, perform personal hygiene); social activity (e.g. get along with family, count on partner's help); zest for life (e.g. enjoy life); and medical treatment (e.g. believe in success of treatment).
Quality of life was assessed before treatment, 8, 24, and 48 weeks after initiation of treatment, and 24 weeks after the end of treatment. Virologic nonresponders who discontinued treatment at week 24 were also followed for 24 weeks after the end of treatment.
For every patient, a sum score of all items of each subscale was used. The scores were transformed onto a scale of 0 (worst possible score) to 100 (best possible score). Differences between the treatment scores and the baseline scores were used to calculate improvement (positive values) or deterioration (negative values) during treatment. Missing items were replaced by the mean of the nonmissing items of the subscales. Missing questionnaires were not replaced.
Statistical analysis
Deterioration of quality of life during and after treatment was investigated in the amantadine and the control group. Comparison of quality of life scores before treatment with quality of life scores during or after treatment was performed with the nonparametric Wilcoxon test for matched pairs. Primary endpoint of the study was a significantly better total sum score of all POMS modalities and all EDLQ modalities from treatment week (TW) 8 to TW48 in patients in the amantadine group compared with patients in the control group. Differences between two groups were investigated with the nonparametric Mann-Whitney U-test. Pretreatment characteristics, virologic response rates, and the number of adverse events of the two groups were compared by the w 2 test. Two-sided P-values r 0.05 were considered significant.
Results
The enrollment criteria were met by 267 patients with chronic hepatitis C. Of these patients, 136 patients were randomized to treatment with amantadine. Patients in the amantadine and in the control group were similar in demographic, biochemical, virologic, and histological characteristics ( Table 1) . During treatment, both groups showed similar adverse events ( Table 2 ). Quality of life was assessed with the POMS scale and the EDLQ. As shown in Fig. 1 , the willingness of the patients to complete and return quality of life questionnaires worsened in the course of the study.
Changes in quality of life during and after treatment are shown in Fig. 2 . Patients in the amantadine and the control group started with similar baseline quality of life scores in all modalities of both questionnaires. Antiviral therapy was initiated with daily induction of IFN-a 9 MU for 2 weeks followed by 6 MU until TW8. At the end of the daily induction period at TW8, quality of life was assessed and compared with baseline. At TW8, patients in the amantadine and the control group showed a significant deterioration of all modalities of the POMS scale and most modalities of the EDLQ compared with baseline (Fig. 2) . The modality medical treatment (e.g. believe in success of treatment) did not worsen in the control group but showed significant deterioration in the amantadine group compared with baseline ( Fig. 2b) .
Between TW8 and TW24, the dose of IFN-a was reduced to 6 MU three times per week. At the end of this period, the modalities depression, fatigue, and vigor showed a significant deterioration compared with baseline in the control group, whereas patients in the amantadine group did not show significant worsening of these modalities ( Fig. 2a ). All remaining modalities but medical treatment showed significant deterioration in both groups.
Patients with a virologic response at TW24 continued treatment with IFN-a 3 MU three times per week for additional 24 weeks until TW48. At TW48, a significant deterioration of the scores for fatigue in the POMS scale was observed in the control group but not in the amantadine group ( Fig. 2a ). To investigate whether amantadine has a significant effect on quality of life during treatment, the total sum scores of all POMS and all EDLQ modalities from TW8 to TW48 were calculated and compared between the amantadine and the control group. Overall, the total sum scores of all POMS modalities and all EDLQ modalities from TW8 to TW48 were not significantly different between patients in the amantadine and the control group.
When antiviral therapy was stopped, a significant posttreatment improvement compared with baseline was observed in the modalities depression, fatigue, and vigor in the control group but only for vigor in the amantadine group (Fig. 2a ). The remaining modalities were similar to baseline in both groups.
Previous studies reported that improvement in quality of life after antiviral treatment is associated with elimination of HCV. Therefore, quality of life changes were analyzed separately in patients who remained viremic during and after treatment (nonresponders), those who showed eradication of HCV after treatment (sustained responders), and those patients who relapsed after treatment (relapsers).
At TW24, nonresponders in the amantadine group showed significant improvement of depression, anger, mind function, everyday life, and zest for life, whereas patients in the control group showed deterioration in all of these modalities compared with baseline ( Fig. 3a) . After stopping of treatment, there was no difference in these modalities between nonresponders in the amantadine and those in the control group.
Next, we compared quality of life between sustained responders in the amantadine and those in the control group. During treatment, sustained virologic responders in the amantadine and the control group showed similar deterioration in quality of life (Fig. 3b ). After treatment, however, there was a significantly stronger improvement of depression in sustained virologic responders in the control group compared with sustained virologic responders who were treated with amantadine (P = 0.007). The remaining modalities were not different between sustained virologic responders in both groups.
Relapsers in the amantadine and the control group showed similar deterioration of quality of life during treatment. After treatment, the modalities body function and social life were better in relapsers in the amantadine group than in those in the control group ( -3. 
Discussion
Health surveys showed that the majority of patients with chronic hepatitis C have a significant impairment of quality of life compared with the healthy population [3, 5, 12] . Treatment options for the reduction of quality of life in patients with chronic hepatitis C are not satisfactory. Amantadine is an antiviral compound [14, 15] , which also effectively reduces fatigue in multiple sclerosis and rigor and tremor in Parkinson's disease [29, 30, 32, 38] . Two previous studies showed that addition of amantadine to IFN-a monotherapy reduced deterioration of quality of life during and after antiviral therapy [26, 28] .
This study was part of a large German placebo-controlled multicenter study comparing triple therapy of IFN-a, ribavirin, and amantadine with IFN-a/ribavirin combination treatment alone in treatment-naive patients with chronic hepatitis C [17] . For assessment of quality of life, we used the POMS scale [34, 35] and an EDLQ related to the SF-36 Health Survey [36, 37] . Both questionnaires were German-adapted and validated [35, 37] .
In this study, different IFN-a doses and frequencies of application were applied. Modalities of quality of life that are mainly influenced by IFN-a should change when the dose and frequency of IFN-a is altered. In this study, all modalities of the POMS scale, and all but one modality of the EDLQ showed dose-dependent deterioration during antiviral therapy indicating that the majority of modalities of quality of life are worsened by IFN-a. Ribavirin may also reduce quality of life. The dose of ribavirin, however, was altered according to the treatment protocol only with respect to adverse events, for example, most frequently anemia. Therefore, modalities of quality of life that are exclusively altered by ribavirin could not be identified in this study.
Previous studies investigating the effects of amantadine on quality of life did not use high dose daily induction treatment with IFN-a [20, [26] [27] [28] . It can be expected that a potential amantadine effect on quality of life is less pronounced when high doses of IFN-a are administered and IFN-a associated deterioration of quality of life is strong. In support of this, we observed a similar deterioration of all modalities of quality of life in the amantadine and the control group at the end of the high dose daily induction period with IFN-a. In the consecutive treatment period, IFN-a was reduced to 6 MU three times per week. At the end of this period, the modalities depression, fatigue, and vigor were still worse compared with baseline in patients in the control group but similar to baseline in patients in the amantadine group. After 48 weeks, when IFN-a was reduced to 3 MU three times per week, fatigue was still worse in the control group compared with baseline but similar to baseline in the amantadine group. These results indicate that amantadine may reduce some adverse effects of IFN-a/ribavirin treatment on quality of life. Similar to the results of this study, a beneficial effect on fatigue and vigor by amantadine has been previously reported in patients with chronic hepatitis C treated with IFN-a monotherapy [28] .
Previous studies showed that quality of life during treatment is not only caused by adverse effects of antiviral therapy but also influenced by the virologic response [10] . In this study, we observed that virologic nonresponders in the amantadine group showed significant improvement of depression, anger, mind function, everyday life, and zest for life compared with nonresponders in the control group at end of treatment. The improvement of these modalities of quality of life in nonresponders treated with amantadine may be explained A previous study has shown that treatment adherence to IFN-a-based antiviral therapy is strongly associated with quality of life during treatment [10] . If amantadine has a strong effect on quality of life, the number of adverse events and the rate of premature discontinuation should be lower in the amantadine group compared with the control group. In this study, however, we observed similar adverse events in the amantadine and the control group [17] . The dropout rates were also not different between the amantadine and the control group.
Overall, the results of this study show only a weak beneficial effect of amantadine on quality of life during treatment, which appears clinically not relevant in the current state of managing hepatitis C. For the treatment of Parkinson's disease, amantadine is used in a dose up to 600 mg/day [29] . In this study, amantadine was given in a much lower dose of only 200 mg/day. It is possible that amantadine may have a stronger effect on quality of life when given at higher doses.
In conclusion, the addition of 200 mg/day amantadine to IFN-a plus ribavirin combination therapy seems to slightly reduce deterioration of quality of life during treatment but does not improve quality of life after the end of treatment.
